GENEVA— Almost one in four patients with advanced lung cancer in Europe, Asia and the US are not receiving EGFR test results before being started on treatment—according to a report presented at the European Lung Cancer Conference by James Spicer MRCP PhD, a consultant in medical oncology at Guy’s Hospital, King’s College London. He explained his concern to Oncology Times reporter Peter Goodwin that anti-EGFR therapies are not being deployed optimally and that outcomes are negatively impacted.
Lack of EGFR Mutation Test Results Before Starting First Line Therapy for Advanced Lung Cancer Worsens Outcomes
Further reading
Babies Use Object Permanence To Get What They Want 2022: A report from the journal: Pediatric Physical Therapy Regina Harbourne PhD, PT, PCS, FAPTA...
Mandeep Mehra talks about his report in the New England Journal of Medicine on the inflammatory effects of COVID-19 infection and the implications...
January 2020 Pediatric Physical Therapy journal highlights the importance of non-billable tasks that are essential to achieving good outcomes. The...
SOURCE: Pediatric Physical Therapy journal ARTICLE “Trends in Attitudes and Practice Patterns of Physical Therapists in Addressing Childhood...
Uptake of the Congenital Muscular Torticollis Guidelines Survey findings about the effectiveness of a recently-introduced clinical practice guideline...
BARCELONA—A new pencil beam scanning proton delivery technique—rescanning—could help limit the dose of radiation to surrounding tissues and organs by...